Iroko launches Zorvolex in Lebanon for acute and chronic pain
In December last year, the Republic of Lebanon Ministry of Public Health (MOPH) approved Zorvolex as a new chemical entity to treat mild to moderate acute pain in
In December last year, the Republic of Lebanon Ministry of Public Health (MOPH) approved Zorvolex as a new chemical entity to treat mild to moderate acute pain in
Chemo Group subsidiary mAbxience is a biopharmaceutical firm specialized in research, development and manufacturing of biosimilars for the treatment and/or prevention of several diseases in diverse therapeutic areas.
Currently, the company is enrolling patients in an open-label multicenter Phase I/II trial, which is designed to evaluate the safety, pharmacokinetics and efficacy of GMI-1271 in combination with
ATL1103 is designed to block growth hormone receptor (GHr) expression thereby reducing levels of the hormone insulin-like growth factor-1 (IGF-1) in the blood and is a potential treatment
Currently, AYX1 is being developed for reduction of acute post-surgical pain and prevention of the transition to persistent or chronic pain with a single administration at the time
SMC has issued its final advice, following a Health Technology Appraisal accepting linagliptin as an additional treatment option for these patients in combination with insulin with or without
Both the parties will investigate potential therapeutics using biotechnology approaches in targeting multiple immune checkpoint modulators to treat immunological diseases including lupus, Sjögren’s Syndrome, inflammatory bowel disease and
The company said that the results support a biologics license application (BLA) for US approval of the vaccine. A total of 4,000 vaccinia-naïve subjects were involved in the
The Re-Circuit trial will compare the use of uninterrupted dabigatran 150mg twice daily to uninterrupted warfarin in AF patients undergoing an ablation procedure. Around 700 patients with either
CG100 is a potentially transformative biologic drug that consists of a recombinant human club cell 10kD protein (rhCC10), a secretory protein. rhCC10 is believed to play a major